argenx SE (NASDAQ:ARGX) Shares Acquired by New Century Financial Group LLC

New Century Financial Group LLC increased its holdings in shares of argenx SE (NASDAQ:ARGX) by 9.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 610 shares of the company’s stock after acquiring an additional 53 shares during the quarter. New Century Financial Group LLC’s holdings in argenx were worth $240,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. GAMMA Investing LLC grew its holdings in argenx by 420.0% in the 1st quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock valued at $31,000 after buying an additional 63 shares in the last quarter. FNY Investment Advisers LLC purchased a new position in argenx during the fourth quarter worth about $38,000. Mather Group LLC. acquired a new stake in shares of argenx during the 1st quarter worth approximately $38,000. Benjamin F. Edwards & Company Inc. purchased a new stake in shares of argenx during the 4th quarter valued at approximately $60,000. Finally, Principal Securities Inc. acquired a new position in argenx in the fourth quarter valued at approximately $99,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on ARGX shares. Piper Sandler lifted their target price on argenx from $522.00 to $535.00 and gave the company an “overweight” rating in a research report on Monday, June 24th. HC Wainwright restated a “buy” rating and issued a $448.00 price objective on shares of argenx in a report on Monday, June 24th. Wedbush reaffirmed an “outperform” rating and set a $519.00 target price on shares of argenx in a research note on Wednesday, June 26th. Bank of America reissued a “buy” rating and issued a $607.00 price target (up from $535.00) on shares of argenx in a research note on Monday, June 24th. Finally, Stifel Nicolaus upped their price objective on shares of argenx from $485.00 to $500.00 and gave the stock a “buy” rating in a report on Monday, June 24th. Five research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $525.42.

argenx Stock Down 0.0 %

Shares of argenx stock opened at $435.29 on Friday. argenx SE has a 52-week low of $327.73 and a 52-week high of $550.76. The company has a market capitalization of $25.87 billion, a P/E ratio of -76.91 and a beta of 0.64. The company has a 50 day moving average of $388.03 and a 200 day moving average of $386.43.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Monday, May 13th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.33). The firm had revenue of $412.51 million during the quarter, compared to analyst estimates of $404.03 million. argenx had a negative net margin of 22.58% and a negative return on equity of 14.14%. During the same quarter in the previous year, the business posted ($0.52) earnings per share. As a group, research analysts anticipate that argenx SE will post -2.92 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.